We are solving one of the most important challenges in pharmacology

…Where success is commensurately rewarded (even in early-stage companies)

Pre-clinical company SQZ Biotechnologies recently completed a deal with Roche involving:

  • - US$125m up-front/near-term;

  • - US$250m clinical, regulatory and sales milestones per product; and

  • - US$1bn developmental milestones

Cell Penetrating Peptides (CPPs) sit on the cusp of clinical validation

Sarepta have taken promising pre-clinical results driven by Cell Penetrating Peptides (CPPs)…

…Into the clinic

mdx mice at 7 weeks of age were treated with a single IV dose of PPMO at 10, 20, 40, or 80 mg/kg and analysed at 30 days post-injection (N=6 mice per group)

i)CPP-PMO (PPMO) is now in Phase 1 trials

ii) multiple follow on CPP-PMO programs are scheduled for IND in 2019

"If the [CP]PPMO tech works, it will not only be fantastic for kids with DMD, but it also allows us to move beyond DMD and into other therapeutic areas"

Sarepta CEO

Efficiency of delivery remains the rate-limiting step in the field

Source:http://investorrelations.sarepta.com/static-files/37f91de4-480e-4429-b453-18ba373fe599

We have the richest and most structurally diverse source library for Cell Penetrating Peptides (CPPs)…

…And we are translating this advantage from the libraries into our 'platform'

Comparison of efficiency of Phylogica's CPPs (orange) with 'conventional' CPPs (blue)

The 3D protein landscape - One of the many dimensions of drug-like properties we are optimising for using advanced analytics to tailor a CPP for particular cargoes and target tissues

Our CPPs deliver more cargo inside cells than competitor CPPs

We have a clear path to translate our differentiation into 'a molecule'

2019

2020

Development stage

MilestoneCargo

Definitive (therapeutic) in vivo read-out

Interim in vivo read-outs

IND-submission

Our technology is highly scalable from this point onwards

Attachments

  • Original document
  • Permalink

Disclaimer

Phylogica Limited published this content on 16 November 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 16 November 2018 03:58:01 UTC